Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 03-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Sales | 19,525 | 20,904 | 26,495 | 18,461 | 22,798 |
| Cost of Goods | 2,662 | 3,001 | 7,642 | 2,248 | 3,014 |
| Gross Profit | 16,863 | 17,903 | 18,853 | 16,213 | 19,784 |
| Operating Expenses | 23,129 | 24,447 | 25,431 | 25,029 | 29,587 |
| Operating Income | -5,604 | -6,543 | -5,936 | -8,568 | -9,789 |
| Other Income | 2,372 | 1,352 | -1,606 | 1,916 | 640 |
| Pre-tax Income | -3,232 | -5,191 | -7,542 | -6,652 | -9,149 |
| Income Tax | 7 | 5 | -752 | 346 | 100 |
| Net Income Continuous | -3,239 | -5,196 | -6,790 | -6,998 | -9,249 |
| Net Income | $-3,239 | $-5,196 | $-6,790 | $-6,998 | $-9,249 |
| EPS Basic Total Ops | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| EPS Basic Continuous Ops | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| EPS Diluted Total Ops | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| EPS Diluted Continuous Ops | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| EPS Diluted Before Non-Recurring Items | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| EBITDA(a) | $-5,551 | $-6,472 | $-5,834 | $-8,447 | $-9,636 |